‘iBreastExam’ uses innovative sensor and material technology combined with software computing to accurately identify cancerous lesions and tumours. It is a breakthrough technology that has the potential to dramatically improve the accessibility and affordability of breast cancer screening. It is a portable, radiation-free and non-invasive US FDA approved device ensuring that the screenings are safe, pain-free and private. Mihir has also proposed an innovative pay-per-use model – instead of targeting direct sales – which will allow doctors in every corner of the country to start screening women for breast cancer at the earliest.
